Podocyturia: A Clue for the Rational Use of Amiloride in Alport Renal Disease
No specific or efficient treatment exists for Alport syndrome, an X-linked hereditary disease caused by mutations in collagen type IV, a crucial component of the glomerular basement membrane. Kidney failure is usually a major complication of the disease, and patients require renal replacement therap...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Case Reports in Nephrology |
| Online Access: | http://dx.doi.org/10.1155/2016/1492743 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832567677094199296 |
|---|---|
| author | H. Trimarchi R. Canzonieri A. Muryan A. Schiel A. Araoz M. Paulero J. Andrews T. Rengel M. Forrester F. Lombi V. Pomeranz R. Iriarte E. Zotta |
| author_facet | H. Trimarchi R. Canzonieri A. Muryan A. Schiel A. Araoz M. Paulero J. Andrews T. Rengel M. Forrester F. Lombi V. Pomeranz R. Iriarte E. Zotta |
| author_sort | H. Trimarchi |
| collection | DOAJ |
| description | No specific or efficient treatment exists for Alport syndrome, an X-linked hereditary disease caused by mutations in collagen type IV, a crucial component of the glomerular basement membrane. Kidney failure is usually a major complication of the disease, and patients require renal replacement therapy early in life. Microhematuria and subsequently proteinuria are hallmarks of kidney involvement, which are due to primary basement membrane alterations that mainly cause endothelial thrombosis and podocyte contraction and ulterior irreversible detachment. Commonly drug-based approaches include angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, which are employed to reduce proteinuria and thus retard kidney disease progression and cardiovascular morbidity and mortality. However, as any hereditary disease, it is expressed as early as in the intrauterine life, and usually an index case is helpful to detect family-related cases. As no specific treatment exists, pathophysiologically based approaches are useful. The present case illustrates the reduction rate of urinary podocyte loss and proteinuria after amiloride administration and suggests the molecular pathways involved in Alport renal disease. Finally, podocyturia rather than proteinuria should be considered as an earlier biomarker of kidney involvement and disease progression in Alport disease. |
| format | Article |
| id | doaj-art-b261dba720d14a14ba017a152ca83242 |
| institution | Kabale University |
| issn | 2090-6641 2090-665X |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Nephrology |
| spelling | doaj-art-b261dba720d14a14ba017a152ca832422025-02-03T01:00:48ZengWileyCase Reports in Nephrology2090-66412090-665X2016-01-01201610.1155/2016/14927431492743Podocyturia: A Clue for the Rational Use of Amiloride in Alport Renal DiseaseH. Trimarchi0R. Canzonieri1A. Muryan2A. Schiel3A. Araoz4M. Paulero5J. Andrews6T. Rengel7M. Forrester8F. Lombi9V. Pomeranz10R. Iriarte11E. Zotta12Nephrology Service, Hospital Britanico de Buenos Aires, Perdriel 74, 1280 Buenos Aires, ArgentinaLaboratory Service, Hospital Britanico de Buenos Aires, Perdriel 74, 1280 Buenos Aires, ArgentinaLaboratory Service, Hospital Britanico de Buenos Aires, Perdriel 74, 1280 Buenos Aires, ArgentinaLaboratory Service, Hospital Britanico de Buenos Aires, Perdriel 74, 1280 Buenos Aires, ArgentinaIFIBIO Houssay, UBA CONICET, Facultad de Medicina, Universidad de Buenos Aires, Paraguay 2155, 1425 Buenos Aires, ArgentinaNephrology Service, Hospital Britanico de Buenos Aires, Perdriel 74, 1280 Buenos Aires, ArgentinaNephrology Service, Hospital Britanico de Buenos Aires, Perdriel 74, 1280 Buenos Aires, ArgentinaNephrology Service, Hospital Britanico de Buenos Aires, Perdriel 74, 1280 Buenos Aires, ArgentinaNephrology Service, Hospital Britanico de Buenos Aires, Perdriel 74, 1280 Buenos Aires, ArgentinaNephrology Service, Hospital Britanico de Buenos Aires, Perdriel 74, 1280 Buenos Aires, ArgentinaNephrology Service, Hospital Britanico de Buenos Aires, Perdriel 74, 1280 Buenos Aires, ArgentinaNephrology Service, Hospital Britanico de Buenos Aires, Perdriel 74, 1280 Buenos Aires, ArgentinaIFIBIO Houssay, UBA CONICET, Facultad de Medicina, Universidad de Buenos Aires, Paraguay 2155, 1425 Buenos Aires, ArgentinaNo specific or efficient treatment exists for Alport syndrome, an X-linked hereditary disease caused by mutations in collagen type IV, a crucial component of the glomerular basement membrane. Kidney failure is usually a major complication of the disease, and patients require renal replacement therapy early in life. Microhematuria and subsequently proteinuria are hallmarks of kidney involvement, which are due to primary basement membrane alterations that mainly cause endothelial thrombosis and podocyte contraction and ulterior irreversible detachment. Commonly drug-based approaches include angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, which are employed to reduce proteinuria and thus retard kidney disease progression and cardiovascular morbidity and mortality. However, as any hereditary disease, it is expressed as early as in the intrauterine life, and usually an index case is helpful to detect family-related cases. As no specific treatment exists, pathophysiologically based approaches are useful. The present case illustrates the reduction rate of urinary podocyte loss and proteinuria after amiloride administration and suggests the molecular pathways involved in Alport renal disease. Finally, podocyturia rather than proteinuria should be considered as an earlier biomarker of kidney involvement and disease progression in Alport disease.http://dx.doi.org/10.1155/2016/1492743 |
| spellingShingle | H. Trimarchi R. Canzonieri A. Muryan A. Schiel A. Araoz M. Paulero J. Andrews T. Rengel M. Forrester F. Lombi V. Pomeranz R. Iriarte E. Zotta Podocyturia: A Clue for the Rational Use of Amiloride in Alport Renal Disease Case Reports in Nephrology |
| title | Podocyturia: A Clue for the Rational Use of Amiloride in Alport Renal Disease |
| title_full | Podocyturia: A Clue for the Rational Use of Amiloride in Alport Renal Disease |
| title_fullStr | Podocyturia: A Clue for the Rational Use of Amiloride in Alport Renal Disease |
| title_full_unstemmed | Podocyturia: A Clue for the Rational Use of Amiloride in Alport Renal Disease |
| title_short | Podocyturia: A Clue for the Rational Use of Amiloride in Alport Renal Disease |
| title_sort | podocyturia a clue for the rational use of amiloride in alport renal disease |
| url | http://dx.doi.org/10.1155/2016/1492743 |
| work_keys_str_mv | AT htrimarchi podocyturiaacluefortherationaluseofamilorideinalportrenaldisease AT rcanzonieri podocyturiaacluefortherationaluseofamilorideinalportrenaldisease AT amuryan podocyturiaacluefortherationaluseofamilorideinalportrenaldisease AT aschiel podocyturiaacluefortherationaluseofamilorideinalportrenaldisease AT aaraoz podocyturiaacluefortherationaluseofamilorideinalportrenaldisease AT mpaulero podocyturiaacluefortherationaluseofamilorideinalportrenaldisease AT jandrews podocyturiaacluefortherationaluseofamilorideinalportrenaldisease AT trengel podocyturiaacluefortherationaluseofamilorideinalportrenaldisease AT mforrester podocyturiaacluefortherationaluseofamilorideinalportrenaldisease AT flombi podocyturiaacluefortherationaluseofamilorideinalportrenaldisease AT vpomeranz podocyturiaacluefortherationaluseofamilorideinalportrenaldisease AT ririarte podocyturiaacluefortherationaluseofamilorideinalportrenaldisease AT ezotta podocyturiaacluefortherationaluseofamilorideinalportrenaldisease |